Coronavirus: Lamaanaha u dhashay Turkiga ee horseedka u ah tallaalka loo helay corona
Nin iyo xaaskiisa, oo kasoo jeeda qoysas qaxooti reer Turki ah, balse hadda heysta dhalashada Jarmalka, ayaa hormuud u ah tallaalka fayraska corona ee dunida looga farxiyay.
Hoggaamiyeyaasha tallaalka: Prof Ugur Sahin (bidix) iyo Dr Özlem Türeci Waxaa loo arkaa inay yihiin dadka nasiibka u yeeshay inay kaalmaha ugu horreeya uga jiraan tartanka lagu suuq geynayo tallaal looga takhaluso fayraska dunida safmarka ku noqday. Howsha ay qabteen waxaa lagu tilmaamay horumar qeyrul-caadi ah. Ugur Sahin, oo Turkiga ku dhashay, da'diisuna tahay 55, waa agaasimaha guud ee shirkadda tiknoolojiyadda caafimaadka ee lagu magacaabo BioNTech - oo laga leeyahay Jarmalka. Waxay shirkaddaas si wadajir ah isula aasaaseen xaaskiisa Özlem Türeci, oo 53 jir ah iyo macallinkiisii hore, Barfasoor Özlem Türeci, oo u dhashay waddanka Austria, kuna takhasusay cudurka kansarka. Muxuu yahay tallaalka lagu farxay? Shirkadda BioNTech iyo shirkadda ay iskaashadaan ee Pfizer, oo laga leeyahay waddanka Mareykanka, waxay ku dhawaaqeen in tallaalka ay soo saareen uu 90% dadka ka difaaci karo inuu jirkooda ku dhaco fayraska corona ee dhaliya cudurka Covid-19, sida lagu ogaaday natiijada wajigii saddexaad ee tijaabada la sameeyay. Wuxuu tallaalkan ka mid yahay 11 tallaal oo hadda maraya marxaladihii ugu dambeeyay ee tijaabada ka socota guud ahaan dunida, waxaana ka qeyb qaadanaya sheybaarro kale iyo shirkado dawooyin soo saara. Adduunka wali horay ugama dhicin dadaal sidaas u xoog badan oo loo galay soo saarista tallaal, horumar noocan ahna lagama sameynin abid. Sida caadiga ah, cilmi baadhista iyo tijaabooyinka tallaalka waxay qaadan jireen toddobo ilaa siddeed sano. Kooxda qaabilsan dawada Covid-19 ee shirkadda BioNTech waxay howshooda ku magacaabeen "Project Lightspeed". Siduu u shaqeyn doonaa tallaalkan? Barfasoor Sahin iyo Dr Türeci waxay ku takhasuseen kobcinta awoodda difaaca jirka, markii horena waxay shaqadooda diiradda ku saari jireen caawinta bukaannada cudurka kansarka. Waxay horay u isticmaaleen qalab loo yaqaanno messenger RNA (mRNA) si ay u sameeyaan dawooyin gaar ah oo lagu durayo unugyada jirka, kuwaasoo kaddib difaaca qofka u tababaraya inuu weeraro unugyada wata cansarka. Barfasoor Sahin ayaa gartay in habka ay u shaqeeyaan qalabka mRNA iyo sida ay dhismaha uga caawiyaan difaaca loo adeegsan karo dagaalka ka dhanka ah fayraska corona. Ujeeddadu waa in unugyada difaaca lagu abuuro burutiinno weerari kara fayraska islamarkii uu jirka soo galo. Markii warka ku saabsan inuu corona dillaacay bishii January laga soo tabiyay magaalada Wuhan ee dalka Shiinaha, shirkadda BioNTech howsheedu meel wanaagsan ayeyba sii mareysay, maadaama ay shaqada lagu abuurayo dawooyinkaas sii billowday sanadkii 2018-kii. Sidoo kale shirkadda Pfizer ayey waqtigaas isla billaabeen diyaarinta tallaal loogu talagalay hargabka. Isniintii waxay mas'uuliyiinta BioNTech shaaciyeen in waxtarka tallaalkooda uu ka sarreeyo 90% - saameyntiisuna ay muuqaneyso hal isbuuc kaddib markii la isticmaalo tallaalka labaad. Qeybta ilaalinta difaaca jirkana waxay billaabaneysaa 28 maalmood kaddib marka la isticmaalo tallaalka koowaad. Waa kuwama lamaanaha awoodda badan? Barfasoor Sahin iyo Dr Türeci waxay shirkadda BioNTech ku aasaaseen magaalada galbeedka Jarmalka ku taalla ee Mainz, sanadkii 2008. Labadoodaba waxaa dhalay waalidiin qaxootinnimo ku tagay Jarmalka. Ugur Sahin afar sano ayuu jiray markii ay qoyskiisa u qaxeen Jarmalka, xilligaasoo ay hooyadiis u tageysay aabihiis oo ka shaqeynayay warshad ku taalla magaalada Cologne. Xarunta shirkadda BioNTech ee magaalada Mainz Ugur Sahin wuxuu cilmiga caafimaadka ka bartay jaamacadda Cologne, wuxuuna sheegay in mar walba uu xilli dambe ku gaadhi jiray sheybaarka jaamacadda. Ilaa maanta shaqada ayuu uga sii dambeeyaa dadka kale. "Waligiis ma uusan baddalin dabeecadda wanaagsan ee aan isla weydina lahayn," Matthias Kromayer oo ah maalqabeen markii ugu horreysayba maalgashaday shirkadda BioNTech. Ka hor inta uusan dillaacin cudurka safmarka ah, BioNTech waxay si gaar ah cilmibaaris ugu sameyn jirtay dawooyinka loo raadinayo kansarka, laakiin ilaa hadda ma jirto daawo ay soo saartay oo la asnixiyay. Özlem Türeci iyaduna waxay soo kordhay aabbeheed oo dhakhtar ah, kaasoo saameyn ku yeeshay xirfadda ay qaadatay, maadaama uu guriga ku sameysan jiray shaqooyinka qaar. "Waligey kuma fikirin xirfad kale xitaa markii aan gabar yar ahaa," ayey tiri mar la wareysanayay. Hadda shirkaddoodu waxay suuqa ka joogtaa $21bn (£16bn), halkii ay sanad ka hor ka ahayd $4.6bn.